News headlines about Medpace (NASDAQ:MEDP) have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Medpace earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave news stories about the company an impact score of 48.6789068265546 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the media headlines that may have effected Accern’s analysis:
- Medpace Holdings Inc (MEDP) Receives Average Rating of “Hold” from Analysts (americanbankingnews.com)
- Critical Review: Blueprint Medicines (BPMC) vs. Medpace (MEDP) (americanbankingnews.com)
- FY2018 Earnings Forecast for Medpace Holdings Inc (MEDP) Issued By William Blair (americanbankingnews.com)
- $97.42 Million in Sales Expected for Medpace Holdings Inc (MEDP) This Quarter (americanbankingnews.com)
Several research analysts have commented on the stock. Zacks Investment Research lowered shares of Medpace from a “buy” rating to a “hold” rating in a research note on Tuesday, October 24th. Robert W. Baird lifted their price objective on shares of Medpace from $32.00 to $35.00 and gave the stock a “neutral” rating in a research note on Tuesday, October 31st. BidaskClub lowered shares of Medpace from a “hold” rating to a “sell” rating in a research note on Tuesday, December 5th. KeyCorp reaffirmed a “hold” rating on shares of Medpace in a research note on Tuesday, October 17th. Finally, Jefferies Group lifted their price objective on shares of Medpace from $34.00 to $38.00 and gave the stock a “hold” rating in a research note on Wednesday, November 1st. Seven research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $36.60.
Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, October 30th. The company reported $0.40 EPS for the quarter, topping the consensus estimate of $0.36 by $0.04. The company had revenue of $98.68 million during the quarter, compared to analyst estimates of $96.84 million. Medpace had a net margin of 6.44% and a return on equity of 10.00%. Medpace’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.40 earnings per share. equities analysts anticipate that Medpace will post 1.5 EPS for the current fiscal year.
In other news, major shareholder Medpace Limited Partnership sold 4,600,000 shares of Medpace stock in a transaction on Tuesday, December 5th. The stock was sold at an average price of $30.16, for a total transaction of $138,736,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 25.80% of the stock is currently owned by company insiders.
Medpace Company Profile
Medpace Holdings, Inc is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support.
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.